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Abstract
Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder. Despite considerable investigation,
the pathogenesis of ITP remains incompletely understood, and for many patients, effective therapy is still
unavailable. Using murine models and in vitro studies of human blood samples, we recently identified a novel
Fc-independent platelet clearance pathway, whereby antibody-mediated desialylated platelets can be cleared in
the liver via asialoglycoprotein receptors, leading to decreased response to standard first-line therapies targeting
Fc-dependent platelet clearance. Here, we evaluated the significance of this finding in 61 ITP patients through
correlation of levels of platelet desialylation with the efficacy of first-line therapies. We found that desialylation
levels between different responses to treatment groups were statistically significant (p < 0.01). Importantly,
correlation analysis indicated response to treatment and platelet desialylation were related (p < 0.01), whereby
non-responders had significantly higher levels of platelet desialylation. Interestingly, we also found secondary ITP
and certain non-ITP thrombocytopenias also exhibited significant platelet desialylation compared to healthy
controls. These findings designate platelet desialylation as an important biomarker in determining response to
standard treatment for ITP. Furthermore, we show for the first time platelet desialylation in other non-ITP
thrombocytopenias, which may have important clinical implications and deserve further investigation.
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Introduction
Immune thrombocytopenia (ITP) is a common clinical
bleeding disorder characterized by an immune-mediated
clearance of autologous platelets, predominantly through
autoantibodies targeting platelet surface receptors GPII-
bIIIa and/or GPIb-IX and clearance by phagocytic cells
in the reticuloendothelial system via Fcγ-receptors [1–4].
Low platelet counts place ITP patients at risk for severe
bleeding including fatal intracranial hemorrhage. Most
therapies for ITP including first-line corticosteroids and
immunoglobulin G (IVIG), and last resort splenectomy,
mainly target the Fc-dependent clearance pathway via
blocking/attenuating Fc-Fcγ-R interaction or removal of
putative site of platelet clearance [4]. However, the
pathogenesis and mechanisms of therapies remain
poorly understood and around 15–20% of ITP patients
are inexplicably refractory to first-line therapies, and
around 10% are refractory to splenectomy [5, 6]. In re-
cent years, murine models and large cohort human stud-
ies report antibody specificity (i.e., anti-GPIIbIIIa versus
anti-GPIb-IX) may play a significant role in dictating
response to therapy in ITP [7–9]; whereby presence of
anti-GPIb-IX antibodies results in decreased response to
corticosteroids and IVIG [7–9]. Most recently, we re-
ported that anti-GPIbα and some anti-GPIIbIIIa anti-
bodies in humans induced platelet desialylation leading
to Fc-independent platelet clearance in the liver via hep-
atic asialoglycoprotein Ashwell-Morell receptors [10],
suggesting antibody-mediated desialylation may be one
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of the underlying mechanisms behind resistance to
standard ITP therapies [8, 9, 11].
In the present study, we sought to address whether in-
creased platelet desialylation was correlated with decreased
response to treatment in ITP patients (Additional file 1:
Supplementary Material). The platelets of randomly and
consecutively enrolled 61 patients diagnosed with primary
ITP were tested for desialylation prior to the indicated
treatments (Table 1). Fluorescein-conjugated lectins Ricinus
communis agglutinin I (RCA-1) and Erythrina cristagalli
lectin (ECL) were used to detect desialylated galactose and
β-GlcNAc residues via flow cytometry. We found the plate-
lets of ITP patients had significantly higher desialylation as
measured by both RCA-1 and ECL binding compared to
those of healthy blood donors (p < 0.05) (Fig. 1). The 61
ITP patients subsequently underwent standard first-line
therapy independent of platelet desialylation and MAIPA
assays. After 1 month of treatment, there were 26 complete
responders (CR), 21 responders (R), and 14 non-responders
(NR) (Table 1). Retrospective data analysis using Kruskal-
Wallis rank sum test revealed NR patients had significantly
higher platelet desialylation, as compared to the CR and R
groups (p < 0.01). Correlation analysis indicated that
efficacy and the desialylation level are related (RCA-1 r =
0.395, p < 0.01; ECL r = 0.391, p < 0.01). The higher desialy-
lation, the poorer the efficacy of therapy observed.
To test whether the presence of anti-GPIbα antibodies
is associated with the platelet desialylation, we detected
antibody using MAIPA in the available 33 patient sam-
ples collected prior to treatment. We observed a two- to
sixfold increased platelet desialylation in patients with
anti-GPIbα antibodies (n = 9) compared to that in pa-
tients with anti-GPIIbIIIa (n = 14) or without detectable
antibodies (n = 10) (Table 1 and Fig. 1B). However, stat-
istical significance was not reached, which is likely due
to small sample size. Future larger studies should be use-
ful in determining direct correlation between anti-GPIbα
antibody positivity with platelet desialylation.
Interestingly, we also observed significant platelet
desialylation in patients with non-ITP thrombocytope-
nias including connective tissue diseases (CTD), myelo-
dysplastic syndrome (MDS), and aplastic anemia (AA)
(p < 0.001) but not acute myeloid leukemia (AML) com-
pared to healthy controls (Table 1 and Fig. 1B). Notably,
although RCA-1 and ECL measures different types of
deglycosylation, we did not observe significant difference
between these two assays, suggesting either of them can
be used for the potential diagnosis and prognosis.
In summary, our data demonstrates for the first
time that the higher level of platelet desialylation is
correlated with non-response to the first-line ITP
therapies (likely also splenectomies; Additional file 1:
Table 1 Platelet desialylation of different groups [M (P25, P75)]
Age Gender (M/F) PLT (×109/L) RCA-1 (%) ECL (%)
ITP (n = 61) 43 ± 18 18/43 16.0 ± 12.5 1.60 (0.50,8.50) 1.30 (0.30,5.05)
Efficacy grouping (n = 61)
CR (n = 26) 36 ± 16 4/22 16.1 ± 15.3 1.10 (0.30,2.05) 0.85 (0.28,1.90)
R (n = 21) 44 ± 19 10/11 17.2 ± 10.5 1.80 (0.65,5.75) 1.00 (0.30,2.05)
NR (n = 14) 52 ± 17 4/10 13.9 ± 9.7 32.95 (4.40,62.20) 20.60 (2.83,34.68)
Antibody grouping (n = 33)
Anti-GPIbα (+) (n = 9) 39 ± 14 2/7 10.7 ± 5.3 2.50 (0.55,24.15) 2.20 (0.45,13.85)
Single anti-GPIIbIIIa (+) (n = 14) 35 ± 16 3/11 16.0 ± 14.5 0.55 (0.18,1.70) 0.35 (0.10,1.90)
Double negative (n = 10) 41 ± 17 5/5 14.9 ± 9.7 0.65 (0.10,5.50) 1.15 (0.10,2.15)
CTD (n = 10) 43 ± 20 3/7 20.3 ± 20.0 5.15 (1.63,28.85) 2.20 (0.90,14.25)
MDS (n = 10) 51 ± 27 3/7 29.3 ± 18.4 8.75 (1.30,14.03) 5.60 (2.08,16.85)
AA (n = 6) 31 ± 11 4/2 28.2 ± 9.6 0.75 (0.18,18.3) 0.95 (0.10,3.05)
AML (n = 8) 49 ± 19 4/4 19.4 ± 18.6 0.20 (0.13,0.80) 0.03 (0.01,0.50)
Healthy control (n = 20) 41 ± 12 10/10 197.7 ± 61.7 0.10 (0.10,0.30) 0.00 (0.00,0.10)
The platelets of primary ITP patients were collected prior to treatment. Fluorescin-conjugated lectins RCA-1 and ECL were used to detect desialylated galactose
and β-GlcNAc residues on platelets via flow cytometry. Platelets from healthy blood donors (controls) and secondary ITP and non-ITP thrombocytopenic patients
were also studied. Normal distribution measurement data is presented as mean ± SEM; skewed distribution measurement data is presented as M (P25, P75), in
which M represents the median, P25 and P75 represent the 25th percentile and 75th percentile, respectively. Kruskal-Wallis rank sum test showed platelet desialylation is
significantly higher in ITP patients as compared to that in healthy blood donors (RCA-1 Z = −4.918, p < 0.001; ECL Z = −5.512, p < 0.001). The course of therapies was
independent from the platelet desialylation assays. The RCA-1 and ECL-positive platelets in non-responder (NR) group are significantly higher than those in complete
responder (CR) and responder (R) groups (RCA-1 χ2 = 10.581, p < 0.01; ECL χ2 = 13.741, p < 0.005). No significant difference was observed between CR and R groups
(p > 0.05). Correlation analysis indicated that as platelet desialylation increases, the efficacy of therapy decreases. Higher platelet desialylation in ITP patients
with anti-GPIbα antibodies was observed as compared with other ITP patients although statistical difference was not reached (RCA-1 χ2 = 3.729, 0.16 > p > 0.05;
ECL χ2 = 3.864, 0.15 > p > 0.05). Higher levels of platelet desialylation were also observed in patients of CTD (systemic lupus erythematosus, n = 6; sicca syndrome,
n = 4) with thrombocytopenia; MDS and AA as compared with healthy controls (RCA-1 χ2 = 33.790, p < 0.001; ECL χ2 = 42.992, p < 0.001). There is no statistical difference
in platelet desialylation between the AML patients and healthy donors (p > 0.05)
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Supplementary Material). These findings not only sug-
gest that platelet desialylation is a useful biomarker in pre-
dicting response to treatment in clinical ITP but positions
sialidase inhibitors, such as Tamiflu [12], as a potential
novel therapeutic in the treatment of ITP as well as other
thrombocytopenias.
Fig. 1 A Platelet desialylation in representative patients and healthy controls. The RCA-1 and ECL binding to platelets from healthy blood donors
(a, b), responder (c, d), and non-responder patients (e, f) were examined by flow cytometry. The representative dot plots from each group are
shown. B Platelet desialylation in different patient groups and healthy controls. The RCA-1 and ECL levels (Mean ± SEM) in complete responders
(CR), responders (R) and non-responders (NR) (a, b); anti-GPIbα antibody positive (+) group, single anti-GPIIb/IIIa antibody (+) group, and double
negative group (c, d); and in the thrombocytopenias/controls (e, f) (ITP, CTD, MDS, AA, AML, and healthy controls) were examined by flow cytometry.
Each point represents the level of platelet desialylation of an individual patient or healthy blood donor (**p < 0.01; ***p < 0.001)
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